A Case of Neuropsychiatric Systemic Lupus Erythematosus as A Sequela of Kikuchi’s Disease
DOI:
https://doi.org/10.19166/med.v10i2.7024Keywords:
Kikuchi’s disease, Systemic lupus erythematosus, Neuropsychiatric systemic lupus erythematosus, Case reportAbstract
The aetiology of Kikuchi’s Disease (KD), a benign condition associated with multiple lymph node enlargements, remains unknown but several reported cases associate it with systemic lupus erythematosus (SLE). A 34-year-old Indonesian woman presented with multiple painless lymph node enlargements around the neck with three weeks of fever, myalgia, arthralgia, night sweats, and weight loss. Laboratory examination showed pancytopenia and elevated ESR. HIV and tuberculin skin testing were negative. Lymph node biopsy confirmed the diagnosis of KD. One week later, despite improvement in lymphadenopathy, she developed fever. Her ANA, anti-Smith antibodies, and anti-Ribosomal-P protein antibodies were positive. She was diagnosed with SLE and managed as an inpatient with high dose methylprednisolone. One week later, the patient developed psychotic symptoms and fever. The results of Laboratory examinations with lumbar puncture were unremarkable. She was diagnosed with neuropsychiatric SLE (NPSLE) and managed with methylprednisolone, paracetamol, folic acid, alprazolam, and amitriptyline. One month later, the patient returned with three days of fever and dyspnea. Despite improvement in neuropsychiatric symptoms, pneumonia and tonsillopharyngitis were diagnosed based on physical examination and chest X- rays. Her condition deteriorated into septic shock. She suffered cardiac arrest and was pronounced dead, despite attempted resuscitation.While KD is a benign condition, diagnosis is challenging due to its rarity and similarity to other lymphadenopathy diseases. Its association with SLE and NPSLE carries poor prognosis with higher mortality rate from the disease progression and adverse medication effects. Thus, early intervention and prevention of complications are crucial in managing patientswith KD.References
1. Bosch X, Guilabert A. Kikuchi-Fujimoto disease. Orphanet J Rare Dis. 2006;3:3-5
2. Humphreys S, Oikonomou KG, Ward N, Aye M. Kikuchi Disease : The Great Masquerador - A Case Report and Review of the Literature. Med Case Rep. 2018; 62:1-4. http://dx.doi.org/10.21767/2471-8041.100097
3. Rahman MSU, Muktadir G, Ahmed SAM. Case Report Kikuchi’s Disease : A Case Report. Faridpur Med Coll J. 2013;8:96-8. https://doi.org/10.3329/fmcj.v8i2.20395
4. Bosch X, Guilabert A, Miquel R, Campo E. Enigmatic Kikuchi-Fujimoto Disease A Comprehensive Review. Am J Clin Pathol. 2004;122:141-52. https://doi.org/10.1309/yf08-1l4t-kywv-yvpq
5. Soedibyo S. Kikuchi-Fujimoto Disease. Med J Indones. 2005;14:107-13. https://doi.org/10.13181/mji.v14i2.178
6. Deaver D, Horna P, Cualing H, Sokol L. Pathogenesis , Diagnosis , and Management of Kikuchi - Fujimoto Disease. Cancer Control. 2014;313-21. https://doi.org/10.1177/107327481402100407
7. Pepe F, Disma S, Teodoro C, Pepe P, Magro G. Kikuchi-Fujimoto disease: A clinicopathologic update. Pathologica. 2015;107:120-9.
8. Baenas DF, Diehl FA, Salinas MJH, Riva V, Diller A, Lemos PA. Kikuchi - Fujimoto disease and systemic lupus erythematosus. Int Med Case Rep J. 2016;9:163-7. https://doi.org/10.2147%2FIMCRJ.S106396
9. Vithoosan S, Karunarathna T, Shanjeeban P, Piranavan P, Matthias T, Gamlaksha D, et al. Kikuchi-Fujimoto disease associated with systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: A case report. J Med Case Rep. 2019;13:1-7. https://doi.org/10.1186%2Fs13256-019-2100-1
10. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM. Introducing polyautoimmunity: Secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012;1. https://doi.org/10.1155%2F2012%2F254319
11. Perry AM, Choi SM. Kikuchi-Fujimoto Disease: A Review. Arch Pathol Lab Med. 2018;142: 1341-6. https://doi.org/10.5858/arpa.2018-0219-ra
12. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol [Internet]. 2012;24:651-7. Available from: http://dx.doi.org/10.1016/j.coi.2012.10.004
13. Haddad J, Shammaa D, Abbas F, Mahfouz RAR. First report on HLA-DPA1 gene allelic distribution in the general Lebanese population. Meta Gene [Internet]. 2016;8:11-3. Available from: http://dx.doi.org/10.1016/j.mgene.2016.01.004
14. Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, et al. Human leukocyte antigens and systemic lupus erythematosus: A protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One. 2014;9:1-7. https://doi.org/10.1371%2Fjournal.pone.0087792
15. Padhan P, Tripathy KP, Sahoo SR, Maikup D, Mahapatra N. Kikuchi - Fujimoto Disease Presenting as Pyrexia of Unknown Origin. Indian J Rheumatol 2018;13:56-9. http://dx.doi.org/10.4103/injr.injr_101_17
16. López-villegas VJ, Medina-morales DA, Alzate-piedrahita JA, Aguirre AM, Rivera LMS. Kikuchi-Fujimoto disease in a patient with systemic lupus erythematosus and generalized lymphadenopathy. Rev Colomb Reumatol. 2018; 25: 216-20.
17. Neto NSR, Bonfiglioli KR, Milanez FM, Macêdo PA, Levy-Neto M. Lymphadenopathy and systemic lupus erythematosus. Bras J Rheumatol. 2010;50:96-101.
18. Dalton J, Shaw R, Democratis J. Case Report Kikuchi-Fujimoto disease. Lancet [Internet]. 2014;383:1098. Available from: http://dx.doi.org/10.1016/S0140-6736(14)60262-2
19. Santana A, Lessa B, Galrão L, Lima I, Santiago M. Kikuchi-Fujimoto’s disease associated with systemic lupus erythematosus : case report and review of the literature. Clin Rheumatol. 2005;24:60-3. https://doi.org/10.1007/s10067-004-0923-6
20. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism / American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;0:1-13. https://doi.org/10.1136/annrheumdis-2018-214819
21. Bichile LS, Chewoolkar VC. Lupus Flare : How to Diagnose and Treat. Med Updat 2011;281-6. https://doi.org/10.31138%2Fmjr.28.1.4
22. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76:459-83. https://doi.org/10.1007/s40265-015-0534-3
23. Pradhan V, Patwardhan M. Neuropsychiatric manifestations and associated autoantibodies. Rheumatol Int. 2015;541-5. https://doi.org/10.1007/s00296-014-3114-z
24. Zhang Y, Han H, Chu L. Neuropsychiatric lupus erythematosus: Future directions and challenges; a systematic review and survey. Clinics. 2020;75:1-7. https://doi.org/10.6061%2Fclinics%2F2020%2Fe1515
25. Jung JY, Yoon D, Choi Y, Kim HA, Suh CH. Associated clinical factors for serious infections in patients with systemic lupus erythematosus. Sci Rep [Internet]. 2019;9:1-8. https://doi.org/10.1038/s41598-019-46039-5
26. Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2019;9:9704. https://doi.org/10.3904/kjim.2016.234
27. Garcia-Cavazos R, Brey R. Neuropsychiatric systemic lupus erythematosus. Systemic Lupus Erythematosus. 4th Ed. 2004;757-83.
28. Ruiz-irastorza G, Olivares N, Ruiz-arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:1-8. https://doi.org/10.1186/ar2764
29. Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus. 2018;1819-27. https://doi.org/10.1177/0961203318792352
30. Kang D, Mok CC. Management of Psychosis in Neuropsychiatric Lupus. J Clin Rheumatol Immunol. 2019;19:9-17. https://doi.org/10.1142/S2661341719300015
31. Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019;6:1-10. https://doi.org/10.1136/lupus-2018-000310
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.